$PRVA

Mountcastle David sold $589K of PRVA

Mountcastle David (EVP & Chief Financial Officer) sold 21,275 shares of Privia Health Group, Inc. (PRVA) at $27.67 ($0.59M total) on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mountcastle David
Published Jul 13, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRVA
Neutral
high confidence
Mentioned
$PRVA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRVANeutralLow
01

Why it matters

The newest fact is the specific sale size, price ($27.6700), and post-transaction holdings (164,853 shares), but it does not include any new corporate event or guidance.

02

Market read

Traders may note the insider sale for positioning, but the planned nature and lack of fundamental updates make it low signal.

03

What to watch

The disclosure does not indicate whether additional sales occurred under the same plan, nor does it reveal tax or diversification motives.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-13 after-hours; reflects sale executed 2026-07-09.

Background

The article is a SEC Form 4 insider transaction for Privia Health Group, Inc., reported by the CFO.

Company-level read

Ticker impact

$PRVANeutralHigh confidence
Context

Privia Health Group CFO David Mountcastle sold 21,275 shares in an open-market transaction for about $588.7K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction should be muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company fundamentals or guidance.

Market effects

No clear read-across to healthcare services or managed care; this is company-specific insider trading.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with insider expectations of near-term risk, so traders may still watch for follow-on selling patterns.

Key entities

  • Privia Health Group, Inc.

    Subject of the Form 4 insider sale by its CFO under a 10b5-1 plan.

  • David Mountcastle

    EVP and Chief Financial Officer who reported the open-market sale.

Related articles

$PRVAHighAI 9/10

Privia Health Group, Inc. (PRVA): Results of Operations and Financial Condition

Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for